N/A N=183 Stepped Care for Children After Trauma: Optimizing Treatment
Posttraumatic Stress Disorder
Primary: Trauma Symptom Checklist for Young Children Posttraumatic Stress Symptoms — 36.00; 35.57 score on a scale — p=.006
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Metastatic Castrate-resistant Prostate Cancer · mCRPC
Primary: Time to Progression — 11.2 weeks
Phase 2 N=563 An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
Early Stage HER2+ Breast Cancer
Primary: Percentage of Patients With Grade 3 or Higher Diarrhea, According to NCI CTCAE v4.0. — 30.7; 28.1; 20.6; 32.7 Percentage of participants
Phase 2 N=96 Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Objective Tumour Response Evaluated According to the Response Evaluation Criteria in Solid Tumours (RECIST 1.0) by Central Review of the Tumour Images — 2; 0; 0; 0…
Phase 2 N=11 Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 1; 1; 7; 1 participants
Phase 2 N=45 Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children
New Daily Persistent Headache (NDPH)
Primary: Pain Intensity — 5.82; 4.92 score on a scale
Phase 2 N=107 Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
Small Cell Lung Cancer
Primary: Duration of Severe (Grade 4) Neutropenia in Cycle 1 — 0; 4 days — p=<0.0001
Phase 3 N=113 Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy
Retinopathy of Prematurity (ROP)
Primary: Proportion of Participants With Absence of Active ROP and Unfavorable Structural Outcomes — 0.855; 0.821 Proportion of participants
Phase 2 N=21 Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
Plaque Psoriasis
Primary: Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs) — 12; 6; 2; 0 Participants
Phase 2 N=127 Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer
Early Stage Breast Cancer
Primary: Rate of Paclitaxel Treatment Completion Within 7 Weeks — 90 percentage of participants
Phase 3 N=148 Use of Perioperative Pain Blocks In Urological Surgery
Pain, Postoperative · Nerve Block · Robotic Surgical Procedures
Primary: Visual Analog Scale (VAS) — 1.29; 3.16; 2.89 score on a scale
N/A N=19 Effects of Audiovisual Distraction on Desaturation and Airway Intervention in OSA-patients
Obstructive Sleep Apnea (OSA)
Primary: Desaturations — 0; 1 number of desaturation events
Phase 2 N=40 Single-Dose Administration Trial of TLC599 in Osteoarthritis of the Knee
Osteoarthritis of the Knee
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 9; 9 Participants
Phase 3 N=42 Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
Hypothalamic Obesity
Primary: Percent Change of Body Mass Index (BMI) as Calculated by the Formula: Body Weight in kg Divided by Height in Meters². — 1.7; 3.5 percent change from baseline — p=0.40
N/A N=10 Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab
JIA Associated Uveitis
Primary: Number of Participants Reported as Complete Responders to Golimumab — 8 Participants